Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Lexaria Bioscience Corp.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
From Lexaria Bioscience Corp.
Via GlobeNewswire
Tickers LEXX
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
From Lexaria Bioscience Corp.
Via GlobeNewswire
Tickers LEXX
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
From Lexaria Bioscience Corp.
Via GlobeNewswire
Tickers LEXX
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
From Lexaria Bioscience Corp.
Via GlobeNewswire
Tickers LEXX
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
From Lexaria Bioscience Corp.
Via AccessWire
Exposures Product Safety
Tickers LEXX LEXXW
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
From Lexaria Bioscience Corp.
Via AccessWire
Topics Supply Chain
Exposures Supply Chain
Tickers LEXX LEXXW
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers LEXX LEXXW
Lexaria's Human Nicotine Study Nearing Start Date
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers LEXX LEXXW
Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Signs Manufacturing and License Agreements with BevNology
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Grants License to AnodGen Bioceuticals
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
From Lexaria Bioscience Corp.
Via AccessWire
Exposures Product Safety
Tickers LEXX LEXXW
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Grants License to Valcon Medical for the European Market
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis
Exposures Cannabis
Tickers LEXX LEXXW
Lexaria Announces 2022 Annual Meeting Results
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers LEXX LEXXW
Lexaria Commences Multi-Week Human Clinical Hypertension Study
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Granted Important New Oral Nicotine Patent
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers LEXX LEXXW
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Provides Annual Letter From the CEO
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Tickers LEXX LEXXW
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
From Lexaria Bioscience Corp.
Via AccessWire
Topics Death Intellectual Property
Exposures Death Intellectual Property
Tickers LEXX LEXXW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.